Fig. 4 | Leukemia

Fig. 4

From: Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Fig. 4

Overall response rate per investigator assessment with first-line ibrutinib. Cumulative best response over time in all patients. Percentages of patients in each category of response may not total the overall proportion with a response because of rounding. CR complete response, CRi complete response with incomplete marrow recovery, nPR nodular partial response, ORR overall response rate, PR partial response, PR-L partial response with lymphocytosis, SD stable disease

Back to article page